Cross-Cutting Engineering

Pharma Formulation Support

Develop and optimize inhalation and nasal formulations for stability, performance, and delivery using lab-scale formulation tools.

We support solutions, suspensions, and dry powders with spray drying, milling, bench chemistry, and HPLC testing for API and impurities.

ISO 17025USP <601>ICH Q8 / Q9 / Q10FDA MDI / DPI / nasalReviewed 2026-05-16
Request a quoteTalk to a scientist

Purpose & when to use

Pharma formulation support helps inhalation and nasal teams turn active, excipient, solvent, propellant, and process choices into testable solution, suspension, and dry-powder candidates. Low-temperature spray drying, milling, pH, osmolality, and HPLC assay or impurity checks connect development-stage CMC decisions to USP <601>, FDA MDI / DPI / nasal, and ISO 17025 quality expectations:

  1. FDA development-stage CMC screening for MDI, DPI, nebulizer, or nasal prototypes using excipient, solvent, propellant, and preservative design matrices.
  2. USP <601> inhalation formulation iteration using spray drying, milling, and paired PSD or emitted-dose checks for candidate powders.
  3. ICH Q8 / Q9 / Q10 risk-based formulation studies using HPLC, pH, and osmolality data to rank stability and manufacturability risks.
  4. FDA MDI / DPI / nasal comparability support using matched batches, controlled process logs, and performance tests after formulation or component changes.
  5. USP <1601> nebulization support using suspension or solution optimization, re-dispersion checks, and aerosol-output readouts for liquid formulations.

Use pharma formulation support when composition, processing, or storage behavior could change aerosol performance, impurity profile, or dose consistency. The method plan links formulation variables to the downstream tests needed for the next CMC decision.

Built for inhalation, nasal, and spray formulations

Formulation programs serve drug-delivery and spray platforms where FDA, USP, ICH, and device constraints shape composition, process choice, and performance confirmation.

  • MDIPropellant-based inhalation
  • DPIDry-powder delivery
  • NebulizerLiquid aerosol formulations
  • Nasal sprayPump and unit-dose
  • Oral spraySolution and suspension formats

Instrumentation & measurement ranges

Lab-scale formulation tools are selected by dosage form, thermal limits, batch size, and the downstream performance question.

1 - 100 gbatch

Low-temperature spray dryer

Small-batch powder generation for inhalation or nasal candidates with inlet temperature, feed rate, solvent system, and collection conditions documented for each run.

0.1 - 100 gbatch

Ball mill and size-reduction tools

Particle engineering and dispersion control for dry powders or suspensions where size, deagglomeration, or re-dispersion behavior drives performance.

1 - 1000 mLsolution

Rotary evaporator and mixing tools

Solvent handling, concentration adjustment, and composition iteration for solutions, suspensions, and process intermediates before performance testing.

0 - 14 pHassay

Bench chemistry and HPLC

pH, osmolality, API assay, and impurity profiling used to track chemical stability, degradation, and formulation compatibility.

Test method options

MethodStrengthsTradeoffAligned with
QbD formulation screening (design matrix)
  • ICH Q8 / Q9 / Q10 framing links excipient, solvent, propellant, and process factors to declared risk drivers.
  • HPLC, pH, and osmolality checks rank chemical stability, compatibility, and manufacturability before larger batches.
Requires a target profile and factor ranges before screening can start.
ICH Q8 / Q9 / Q10
Dry powder development (spray drying and milling)
  • USP <601> context supports candidate powders that can move into PSD and emitted-dose confirmation.
  • Spray-drying and milling logs capture temperature, feed, solvent, and handling variables for repeatable batches.
Moisture, thermal exposure, and powder handling can limit candidate throughput.
USP <601>
Suspension and solution optimization (bench chemistry)
  • FDA MDI / DPI / nasal framing ties viscosity, preservative, propellant, and re-dispersion choices to CMC decisions.
  • USP <1601> context supports nebulized liquids when aerosol output or solution behavior is part of the question.
Iterative batches and storage pulls can extend timelines when stability changes slowly.
FDA MDI / DPI / nasalUSP <1601>

Setup configurations

A formulation support study starts with the decision the customer needs: screen factors, make a powder, improve a suspension, or link stability to performance. The setup fixes composition ranges, batch size, process settings, storage state, analytical checks, and paired aerosol tests before materials enter the lab.

Sample matrix

API, excipients, solvent, propellant, preservative, concentration, and composition constraints documented for each candidate.

Exposure profile

Spray-drying, milling, mixing, evaporation, storage, and pull conditions defined before batch preparation.

Sample numbers

Screening runs, confirmatory batches, retained samples, and paired test replicates sized to the formulation decision.

Calibration & verification

Balances, pH, osmolality, HPLC calibration, and process settings checked before and during the campaign.

Chain of custody

Batch labels, preparation records, storage transfers, analytical handoffs, and final disposition recorded for each candidate.

Quality anchors for formulation decisions

Formulation studies need the quality posture defined before screening starts. These anchors frame method controls, batch records, analytical checks, paired performance confirmation, and report language.

  • ISO 17025AccreditedTesting-laboratory competence, traceable records, and method control.
  • USP <601>AccreditedInhalation and nasal performance checks when paired with aerosol testing.
  • ICH Q8 / Q9 / Q10AlignedQbD, risk management, and pharmaceutical quality-system framing.
  • FDA MDI / DPI / nasalAlignedDevelopment-stage CMC and submission-facing expectations for OINDP programs.

Key data outputs & reporting

Every formulation support study delivers the composition, process, analytical, and decision records needed to compare candidates. Reports state batch recipes, process settings, storage history, pH, osmolality, HPLC assay or impurity results, paired aerosol readouts when included, and the rationale for advancing or rejecting each formulation. Data are organized by candidate, factor level, condition, pull point, and endpoint.

Primary outputs

  • Composition and process logs covering batch recipe, spray-drying or milling settings, mixing steps, and storage state.
  • API assay, impurity, pH, osmolality, yield, appearance, and re-dispersion summaries by candidate and condition.
  • Decision tables linking formulation variables to stability, manufacturability, PSD, emitted dose, plume, or aerosol-output outcomes.

Deliverables

#FormatContents
01PDF reportFormulation rationale, methods, controls, results, and candidate-selection logic.
02CSV / XLSX datasetsBatch recipes, process settings, assay results, and trend tables.
03FiguresComparison charts, impurity trends, and formulation-response plots.

QA / QC & data integrity

Formulation decisions depend on knowing exactly how each candidate was prepared, stored, sampled, and measured. QA / QC records therefore cover instrument checks, batch identity, storage state, analytical suitability, repeat preparations, retained samples, reviewer-ready notes, and handoffs from formulation work through aerosol or chemistry readouts.

Calibrated balances, pH meters, osmometers, and HPLC systems verified before use.

Batch records capturing raw materials, lot identity, process settings, yield, appearance, and deviations.

HPLC system suitability, calibration verification, blanks, and sample-sequence controls where assay or impurity data are reported.

Duplicate preparations or confirmatory batches for candidates that advance beyond screening.

Controlled storage, pull-point logs, and chain-of-custody records for retained or stability-linked samples.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
17025Accredited testing
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

Formulation questions usually come from pharmaceutical development, CMC, device, analytical, and regulatory teams deciding how to turn an active and device concept into testable candidates. These answers cover liquids versus powders, excipient screening, impurity tracking, paired aerosol testing, stability links, and deliverables. Reach out if your active, device, or regulatory frame needs a different setup.

Q.Can you support both liquid and dry-powder formulations?
A.Yes. We support solutions, suspensions, and dry powders using mixing, rotary evaporation, spray drying, milling, pH, osmolality, and HPLC checks, then pair promising candidates with aerosol performance tests when needed.
Q.Can you track impurities and degradation?
A.Yes. HPLC assay and impurity profiling can be built into screening or stability-linked pulls so formulation choices are compared against chemical stability, not only appearance or performance.
Q.How do you choose a formulation path?
A.We start from target product profile, device constraints, active stability, route of delivery, and CMC decision. That determines whether the first pass uses solution, suspension, powder, or parallel screening paths.
Q.Can aerosol testing be included with formulation work?
A.Yes. PSD, emitted dose, plume, spray pattern, or aerosol-output studies can be paired with formulation batches so composition changes are tied to delivery outcomes.
Q.What do I receive after the study?
A.Deliverables usually include a PDF report, batch records, CSV or XLSX datasets, assay tables, trend plots, comparison figures, and candidate-selection rationale tied to the agreed decision.

Standards & guidance

Pharma formulation support is scoped around the dosage form, development stage, and next regulatory decision. ARE Labs treats ISO 17025 as the quality-system anchor for traceable testing, applies USP <601> when inhalation aerosol performance is tested, and aligns formulation work to ICH, USP, and FDA guidance where applicable to the program.

QA & Regulatory - Accredited

ISO 17025

Testing-laboratory competence, traceable records, calibration control, and uncertainty contributorsView standard ->Inhalation & Drug Delivery - Accredited

USP <601>

Inhalation and nasal aerosol performance checks used when formulation candidates move into testingView standard ->QA & Regulatory - Aligned

ICH Q8 / Q9 / Q10

Pharmaceutical development, quality risk management, and quality-system framing for QbD studiesView standard ->QA & Regulatory - Aligned

FDA MDI / DPI / nasal

Development-stage CMC and submission expectations for inhalation and intranasal drug productsView standard ->Inhalation & Drug Delivery - Aligned

USP <1601>

Nebulized product characterization context for liquid formulation and aerosol-output studiesView standard ->QA & Regulatory - Aligned

FDA development-stage CMC

Formulation, process, analytical, and comparability rationale during early product developmentView standard ->

Related services & devices

Service

Particle Size Distribution (PSD) Testing

Pairs with formulation work when powders, sprays, or nebulized liquids need respirable or nasal size confirmation.Read more ->Devices

Drug Delivery

MDI, DPI, nebulizer, nasal, and oral spray programs connect formulation choices to device performance.Read more ->Service

Dose Uniformity & Emitted Dose

Confirms whether formulation changes alter per-actuation dose, shot-to-shot consistency, or aerosol output.Read more ->Devices

Spray & Aerosol

Spray products use formulation support when solvent, propellant, or suspension behavior changes delivery.Read more ->